Efficacy of daclizumab HYP across subgroups of varying relapsing-remitting multiple sclerosis disease severity: Results from the SELECT study

Authors
Category Primary study
ConferenceJournal of Neurology
Year 2014
This article has no abstract
Epistemonikos ID: bdec0cea4109154ecaf41c97460c2a98a7cea3a1
First added on: Apr 30, 2026